Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
23.98
+1.07 (+4.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
January 24, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
January 21, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
January 14, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
January 12, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo...
Via
Benzinga
Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities
December 20, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 17, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences
November 30, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead
November 23, 2021
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market...
Via
Benzinga
4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout
November 23, 2021
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.
Via
The Motley Fool
Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript
November 22, 2021
ARWR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
November 22, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
November 22, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
November 22, 2021
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.
Via
Investor's Business Daily
Earnings Scheduled For November 22, 2021
November 22, 2021
Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya...
Via
Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...
Via
Benzinga
Exposures
Product Safety
Earnings Outlook For Arrowhead Pharmaceuticals
November 19, 2021
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 18, 2021
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at...
Via
Benzinga
Arrowhead Announces JNJ-75220795 in Development for NASH
November 17, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
November 15, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
November 15, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
November 12, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
November 12, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
November 01, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
November 01, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
October 25, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
October 12, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
September 30, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.